Passa al contenuto
Merck

Y0001117

Amikacin for system suitability

European Pharmacopoeia (EP) Reference Standard

Sinonimo/i:

Amikacin disulfate salt

Slide 1 of 1
Autenticati per visualizzare i prezzi riservati alla tua organizzazione & contrattuali

Scegli un formato

15 MG

190,00 €

190,00 €

Per informazioni sulla disponibilità, contatta il Servizio Clienti.
Richiedi un ordine in blocco

Informazioni su questo articolo

Formula empirica (notazione di Hill):
C22H43N5O13 · 2H2SO4
Numero CAS:
39831-55-5
Peso molecolare:
781.76
Beilstein:
6172633
Numero MDL:
MFCD00167475
Codice UNSPSC:
41116107
ID PubChem:
329831271
NACRES:
NA.24

Documenti fondamentali

Visualizza tutta la documentazione

Vai a

Servizio Tecnico
Hai bisogno di aiuto? Il nostro team di scienziati qualificati è a tua disposizione.
Permettici di aiutarti

Grado

pharmaceutical primary standard

Famiglia di API

amikacin

Produttore/marchio commerciale

EDQM

applicazioni

pharmaceutical (small molecule)

Formato

neat

Temperatura di conservazione

2-8°C

Stringa SMILE

OS(O)(=O)=O.OS(O)(=O)=O.NCC[C@H](O)C(=O)N[C@@H]1C[C@H](N)[C@@H](O[C@H]2O[C@H](CN)[C@@H](O)[C@H](O)[C@H]2O)[C@H](O)[C@H]1O[C@H]3O[C@H](CO)[C@@H](O)[C@H](N)[C@H]3O

InChI

1S/C22H43N5O13.2H2O4S/c23-2-1-8(29)20(36)27-7-3-6(25)18(39-22-16(34)15(33)13(31)9(4-24)37-22)17(35)19(7)40-21-14(32)11(26)12(30)10(5-28)38-21;2*1-5(2,3)4/h6-19,21-22,28-35H,1-5,23-26H2,(H,27,36);2*(H2,1,2,3,4)/t6-,7+,8-,9+,10+,11-,12+,13+,14+,15-,16+,17-,18+,19-,21+,22+;;/m0../s1
FXKSEJFHKVNEFI-GCZBSULCSA-N

Cerchi prodotti simili? Visita Guida al confronto tra prodotti

Confronta articoli simili

Visualizza il confronto per intero

Mostra le differenze

1 of 4

Questo articolo
A0365900Y0000641Y0000813
Amikacin for system suitability European Pharmacopoeia (EP) Reference Standard

Y0001117

Amikacin for system suitability

Amikacin sulfate European Pharmacopoeia (EP) Reference Standard

A0365900

Amikacin sulfate

Azithromycin for system suitability European Pharmacopoeia (EP) Reference Standard

Y0000641

Azithromycin for system suitability

Bisoprolol for system suitability European Pharmacopoeia (EP) Reference Standard

Y0000813

Bisoprolol for system suitability

grade

pharmaceutical primary standard

grade

pharmaceutical primary standard

grade

pharmaceutical primary standard

grade

pharmaceutical primary standard

manufacturer/tradename

EDQM

manufacturer/tradename

EDQM

manufacturer/tradename

EDQM

manufacturer/tradename

EDQM

application(s)

pharmaceutical (small molecule)

application(s)

pharmaceutical (small molecule)

application(s)

pharmaceutical (small molecule)

application(s)

pharmaceutical (small molecule)

format

neat

format

neat

format

neat

format

neat

API family

amikacin

API family

amikacin

API family

azithromycin

API family

bisoprolol

storage temp.

2-8°C

storage temp.

2-8°C

storage temp.

-

storage temp.

2-8°C

Descrizione generale

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.

Applicazioni

Amikacin for system suitability EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Confezionamento

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Altre note

Sales restrictions may apply.

Prodotti correlati

N° Catalogo
Descrizione
Determinazione del prezzo

Prodotto comparabile

N° Catalogo
Descrizione
Determinazione del prezzo

Pittogrammi

Health hazardExclamation mark
GHS08,GHS07

Avvertenze

Warning

Indicazioni di pericolo

H317,H361fd

Classi di pericolo

Repr. 2 - Skin Sens. 1

Codice della classe di stoccaggio

11 - Combustible Solids

Classe di pericolosità dell'acqua (WGK)

WGK 2

Punto d’infiammabilità (°F)

Not applicable

Punto d’infiammabilità (°C)

Not applicable

Scegli una delle versioni più recenti:

Certificati d'analisi (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Documenti section.

Se ti serve aiuto, non esitare a contattarci Servizio Clienti

Possiedi già questo prodotto?

I documenti relativi ai prodotti acquistati recentemente sono disponibili nell’Archivio dei documenti.

Visita l’Archivio dei documenti

Sabine Ladrech et al.
The European journal of neuroscience, 38(6), 2962-2972 (2013-07-10)
To examine whether an inflammatory process occurs in the amikacin-poisoned cochlea, we investigated the presence of the cytokines tumour necrosis factor-α (TNF-α), interleukin (IL)-1β, and IL-10. No TNF-α, IL-1β or IL-10 was detected in the cochlear perilymph after the loss
Kamal M Matar et al.
BioMed research international, 2013, 202818-202818 (2013-03-14)
Amikacin pharmacokinetic data in Kuwaiti (Arab) intensive care unit (ICU) patients are lacking. Fairly sparse serum amikacin peak and trough concentrations data were obtained from adult Kuwaiti ICU patients. The data were analysed using a nonparametric adaptive grid (NPAG) maximum
Kenneth S Chen et al.
Pediatric blood & cancer, 60(11), 1772-1777 (2013-06-22)
Children undergoing cancer therapy often receive aminoglycosides to treat febrile neutropenia or gram-negative infections. The magnitude of the risk of developing aminoglycoside-induced ototoxicity and the dose threshold at which that risk significantly increases are unknown. Eligible cancer patients received the
Chien-Wen Huang et al.
International journal of antimicrobial agents, 41(3), 218-223 (2013-01-15)
The occurrence of diseases caused by rapidly growing mycobacteria (RGM) is increasing in Taiwan. In this study, the in vitro antimicrobial activities of tigecycline, minocycline, tetracycline and doxycycline were evaluated against 160 clinical RGM isolates, including 34 Mycobacterium abscessus sensu
Irina Debnath et al.
Infection and immunity, 81(5), 1450-1459 (2013-02-23)
Strains of uropathogenic Escherichia coli (UPEC) are the primary cause of urinary tract infections, representing one of the most widespread and successful groups of pathogens on the planet. To colonize and persist within the urinary tract, UPEC must be able
Visualizza tutti i documenti correlati

Domande

Recensioni

Nessuna valutazione

Filtri attivi

Il team dei nostri ricercatori vanta grande esperienza in tutte le aree della ricerca quali Life Science, scienza dei materiali, sintesi chimica, cromatografia, discipline analitiche, ecc..

Contatta l'Assistenza Tecnica